Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Caribou Biosciences announced durable and deep responses from its allogeneic CAR-T cell therapy vispa-cel in a phase 1 trial for relapsed/refractory large B cell lymphoma, demonstrating an 82% overall response rate and 67% complete response rate. The safety profile supports outpatient administration and expanded access, with a pivotal phase 3 trial…